{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Protein+Digestion&page=13",
    "query": {
      "condition": "Protein Digestion",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 298,
    "total_pages": 30,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Protein+Digestion&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Protein+Digestion&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-13T09:29:36.666Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06614192",
      "title": "A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Telisotuzumab Adizutecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2024-11-08",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-11-13T09:29:36.666Z",
      "location_count": 24,
      "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 20 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Golden",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06614192"
    },
    {
      "nct_id": "NCT06586957",
      "title": "A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Advanced Solid Tumor",
        "Solid Tumor, Adult",
        "Metastatic Tumor",
        "Ovarian Cancer",
        "Ovarian Neoplasms",
        "Ovarian Carcinoma",
        "Metastatic Ovarian Carcinoma",
        "Endometrial Neoplasms",
        "Endometrial Diseases",
        "Metastatic Endometrial Cancer",
        "Triple Negative Breast Cancer",
        "Metastatic Endometrial Carcinoma",
        "Advanced Endometrial Carcinoma",
        "Advanced Ovarian Carcinoma",
        "Gastric Cancer",
        "Advanced Gastric Carcinoma",
        "Metastatic Gastric Cancer",
        "Metastatic Gastric Carcinoma",
        "Small Cell Lung Cancer",
        "Small Cell Lung Carcinoma",
        "Triple Negative Breast Neoplasms",
        "Platinum-resistant Ovarian Cancer",
        "Platinum-refractory Ovarian Carcinoma",
        "CCNE1 Amplification",
        "Hormone Receptor Negative Breast Carcinoma",
        "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast",
        "Progesterone-receptor-positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "NKT3964",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NiKang Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 238,
      "start_date": "2024-09-19",
      "completion_date": "2029-05",
      "has_results": false,
      "last_update_posted_date": "2026-11-05",
      "last_synced_at": "2026-11-13T09:29:36.666Z",
      "location_count": 19,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06586957"
    },
    {
      "nct_id": "NCT00899496",
      "title": "Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "immunological diagnostic method",
          "type": "OTHER"
        },
        {
          "name": "physiologic testing",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "Up to 120 Years"
      },
      "enrollment_count": 54,
      "start_date": "2005-09",
      "completion_date": "2009-10-23",
      "has_results": false,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-11-13T09:29:36.666Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00899496"
    },
    {
      "nct_id": "NCT06529523",
      "title": "Tislelizumab in People With Colorectal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Tislelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2024-07-26",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2026-11-06",
      "last_synced_at": "2026-11-13T09:29:36.666Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06529523"
    },
    {
      "nct_id": "NCT04117087",
      "title": "Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "KRAS peptide vaccine",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2020-05-28",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-11-13T09:29:36.666Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04117087"
    },
    {
      "nct_id": "NCT01494909",
      "title": "Development Of An Innovative Panel of Methods To Measure Intestinal Macronutrient Digestion, Absorption, and Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "Ensure plus",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Texas A&M University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2010-11-15",
      "completion_date": "2011-12-07",
      "has_results": false,
      "last_update_posted_date": "2025-10-01",
      "last_synced_at": "2026-11-13T09:29:36.666Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01494909"
    },
    {
      "nct_id": "NCT00788359",
      "title": "Cystic Fibrosis Foundation (CFF) Biomarkers of Exacerbation",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 123,
      "start_date": "2007-12",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2014-12-02",
      "last_synced_at": "2026-11-13T09:29:36.666Z",
      "location_count": 5,
      "location_summary": "Denver, Colorado • Indianapolis, Indiana • Ann Arbor, Michigan + 2 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00788359"
    },
    {
      "nct_id": "NCT01464814",
      "title": "Clinical Trial Evaluating the Viability of L. Casei + Fish Oil Capsules",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Signs and Symptoms, Digestive"
      ],
      "interventions": [
        {
          "name": "probiotic plus fish oil capsule",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Fish oil capsule",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Nutrition 21, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 15,
      "start_date": "2011-10",
      "completion_date": "2011-11",
      "has_results": false,
      "last_update_posted_date": "2011-11-16",
      "last_synced_at": "2026-11-13T09:29:36.666Z",
      "location_count": 1,
      "location_summary": "Pembroke Pines, Florida",
      "locations": [
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01464814"
    },
    {
      "nct_id": "NCT03434262",
      "title": "SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anaplastic Astrocytoma",
        "Anaplastic Ependymoma",
        "Anaplastic Ganglioglioma",
        "Anaplastic Meningioma",
        "Anaplastic Oligodendroglioma",
        "Pleomorphic Xanthoastrocytoma, Anaplastic",
        "Atypical Teratoid/Rhabdoid Tumor",
        "Brain Cancer",
        "Brain Tumor",
        "Central Nervous System Neoplasms",
        "Choroid Plexus Carcinoma",
        "CNS Embryonal Tumor With Rhabdoid Features",
        "Ganglioneuroblastoma of Central Nervous System",
        "CNS Tumor",
        "Embryonal Tumor of CNS",
        "Ependymoma",
        "Glioblastoma",
        "Glioma",
        "Glioma, Malignant",
        "Medulloblastoma",
        "Medulloblastoma; Unspecified Site",
        "Medulloepithelioma",
        "Neuroepithelial Tumor",
        "Neoplasms",
        "Neoplasms, Neuroepithelial",
        "Papillary Tumor of the Pineal Region (High-grade Only)",
        "Pediatric Brain Tumor",
        "Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only)",
        "Pineoblastoma",
        "Primitive Neuroectodermal Tumor",
        "Recurrent Medulloblastoma",
        "Refractory Brain Tumor",
        "Neuroblastoma. CNS",
        "Glioblastoma, IDH-mutant",
        "Glioblastoma, IDH-wildtype",
        "Medulloblastoma, Group 3",
        "Medulloblastoma, Group 4",
        "Glioma, High Grade",
        "Neuroepithelial Tumor, High Grade",
        "Medulloblastoma, SHH-activated and TP53 Mutant",
        "Medulloblastoma, SHH-activated and TP53 Wildtype",
        "Medulloblastoma, Chromosome 9q Loss",
        "Medulloblastoma, Non-WNT Non-SHH, NOS",
        "Medulloblastoma, Non-WNT/Non-SHH",
        "Medulloblastoma, PTCH1 Mutation",
        "Medulloblastoma, WNT-activated",
        "Ependymoma, Recurrent",
        "Glioma, Recurrent High Grade",
        "Glioma, Recurrent Malignant",
        "Embryonal Tumor, NOS",
        "Glioma, Diffuse Midline, H3K27M-mutant",
        "Embryonal Tumor With Multilayered Rosettes (ETMR)",
        "Ependymoma, NOS, WHO Grade III",
        "Ependymoma, NOS, WHO Grade II",
        "Medulloblastoma, G3/G4",
        "Ependymoma, RELA Fusion Positive"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "ribociclib",
          "type": "DRUG"
        },
        {
          "name": "sonidegib",
          "type": "DRUG"
        },
        {
          "name": "trametinib",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "1 Year to 39 Years"
      },
      "enrollment_count": 68,
      "start_date": "2018-03-05",
      "completion_date": "2024-05-24",
      "has_results": false,
      "last_update_posted_date": "2024-05-31",
      "last_synced_at": "2026-11-13T09:29:36.666Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03434262"
    },
    {
      "nct_id": "NCT00445549",
      "title": "Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Neoplasms",
        "Fallopian Tube Neoplasms",
        "Peritoneal Neoplasms"
      ],
      "interventions": [
        {
          "name": "Vandetanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 12,
      "start_date": "2007-01",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2012-06-26",
      "last_synced_at": "2026-11-13T09:29:36.666Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00445549"
    }
  ]
}